RTI to study DTC ad response for FDA

Share this article:

Under a $4-million contract from FDA, RTI International researchers will look at consumers' responses to risk, benefit and cost information in direct-to-consumer prescription drug ads. The studies will include:

• Attentional effects in pharma ad viewing—Eye-tracking technology will be used to better understand consumer attention to risks and benefit information.

• Caregiver influence on consumer perceptions of ads—Individuals who have had a disease and their spouses or partners will react to ads for a drug to treat it.

• Cost comparison effect—RTI will assess how prescription drug TV ads with cost comparison information may affect understanding of differences in safety, efficacy and side effects.

• TV ad frequency's effect on perceptions—Researchers will explore how the frequency of exposure affects consumers' understanding of a drug's risks and benefits.

• Web and mobile technology promotion content analysis—Researchers will conduct content analyses of DTC prescription drug ads.

Share this article:

Email Newsletters

More in Features

Antidote: On Cystic Fibrosis treatments

Antidote: On Cystic Fibrosis treatments

Recent treatments in CF, including the inhaled antibiotic Tobramycin, have increased lifespan well into adulthood.

The $3 generic and the $1,000 pill: pharma outsiders just don't get it

The $3 generic and the $1,000 pill: pharma ...

What do you call the people who treat medical breakthroughs as if they were bank heists? Malicious? Uninformed? Not with it?

Leadership Exchange Uncut : The Agency-Client Relationship

Leadership Exchange Uncut : The Agency-Client Relationship

Click the above link to access MM&M's first Leadership Exchange Uncut e-book, "The Agency-Client Relationship"